World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
31486
World Ranking
17382
National Ranking
8704

Overview

Ravi Vij is affiliated with Washington University in St. Louis in the United States. Their research spans multiple disciplines within medicine and molecular biology, with a specific focus on hematology, oncology, genetics, and immunology. Their work primarily addresses multiple myeloma, protein degradation and inhibitors, CAR-T cell therapy, monoclonal and polyclonal antibodies, chemokine receptors and signaling, chronic lymphocytic leukemia, and hematopoietic stem cell transplantation.

The scientist has published extensively in a variety of academic journals. Their most frequent publication venues include Blood, Clinical Lymphoma Myeloma & Leukemia, Cancer Research, UNC Libraries, and Journal of Clinical Oncology.

Among their recent papers are:

  • Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma, 2023, New England Journal of Medicine
  • LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma, 2022, Leukemia
  • Epigenetic regulation during cancer transitions across 11 tumour types, 2023, Nature
  • Co-evolution of tumor and immune cells during progression of multiple myeloma, 2021, Nature Communications
  • A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM), 2020, Blood

Frequent co-authors collaborating with this scientist include Mark A. Fiala, Mark A. Schroeder, John F. DiPersio, Reyka G. Jayasinghe, and Michael Slade.

Best Publications

  • Initial genome sequencing and analysis of multiple myeloma

    Michael A. Chapman;Michael S. Lawrence;Jonathan J. Keats;Kristian Cibulskis

  • Lenalidomide after stem-cell transplantation for multiple myeloma

    Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd

  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    John S. Welch;Allegra A. Petti;Christopher A. Miller;Catrina C. Fronick

  • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

    David S. Siegel;Thomas Martin;Michael Wang;Ravi Vij

  • Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

    Stefan O. Ciurea;Mei Jie Zhang;Andrea A. Bacigalupo;Asad Bashey

  • Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

    Ajai Chari;Dan T Vogl;Maria Gavriatopoulou;Ajay K Nooka

  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

    Qingsong Gao;Wen-Wei Liang;Steven M Foltz;Gnanavel Mutharasu

  • A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

    Andrzej J. Jakubowiak;Andrzej J. Jakubowiak;Dominik Dytfeld;Dominik Dytfeld;Kent A. Griffith;Daniel Lebovic

  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

    Ujjawal H. Gandhi;Robert F. Cornell;Arjun Lakshman;Zhubin J. Gahvari

  • Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

    Shaji Kumar;Jonathan L. Kaufman;Cristina Gasparetto;Joseph Mikhael

  • SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution.

    Christopher A. Miller;Brian S. White;Nathan D. Dees;Malachi Griffith

  • Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

    Paul G. Richardson;David S. Siegel;Ravi Vij;Craig C. Hofmeister

  • Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

    Iskra Pusic;Shi Yuan Jiang;Scott Landua;Geoffrey L. Uy

  • A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

    Geoffrey L. Uy;Michael P. Rettig;Ibraheem H. Motabi;Kyle McFarland

  • Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Sagar Lonial;Ravi Vij;Jean-Luc Harousseau;Thierry Facon

  • Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

    David Siegel;Thomas Martin;Ajay Nooka;R. Donald Harvey

  • Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

    Steven M. Devine;Ravi Vij;Michael Rettig;Laura Todt

  • An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

    Ravi Vij;Michael Wang;Jonathan L. Kaufman;Sagar Lonial

  • Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

    Drew J. Winston;Jo Anne H. Young;Vinod Pullarkat;Genovefa A. Papanicolaou

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

Frequent Co-Authors

John F. DiPersio
John F. DiPersio Washington University in St. Louis
Peter Westervelt
Peter Westervelt Brown University
David S. Siegel
David S. Siegel Hackensack University Medical Center
Sagar Lonial
Sagar Lonial Emory University
Shaji Kumar
Shaji Kumar Mayo Clinic
Paul G. Richardson
Paul G. Richardson Harvard University
feng gao
feng gao Duke University
Feng Gao
Feng Gao Linköping University
Parameswaran Hari
Parameswaran Hari Medical College of Wisconsin
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in studying medicine in the USA but want to explore flexible or alternative career options, there are several online degrees to consider. Many top institutions now offer accredited programs that allow you to pursue specialized healthcare roles without attending campus full-time.

For example, students interested in pharmacy can enroll in a pharmacy school online accredited program to become licensed professionals in a rapidly evolving field. Those looking into health technology and management can earn an online mhi (Master of Health Information), ideal for careers in health informatics and data management.

If medical administration attracts you, there are billing and coding classes online designed to train specialists for medical billing, insurance, and compliance work. Aspiring nurse practitioners can find most affordable nurse practitioner programs that offer clinical and theoretical training remotely, bridging the demand for advanced practice nurses across the country.

These pathways provide flexible, cost-effective options for those seeking rewarding healthcare careers beyond traditional medical school.

Best Scientists Citing Ravi Vij

Trending Scientists